Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.

A new interesting article has been published in Int J Antimicrob Agents. 2020 Mar 20:105949. doi: 10.1016/j.ijantimicag.2020.105949. [Epub ahead of print] and titled: Hydroxychloroquine and azithromycin as a treatment of…

Continue ReadingHydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.

Imaging Features of Coronavirus disease 2019 (COVID-19): Evaluation on Thin-Section CT.

A new interesting article has been published in Acad Radiol. 2020 Mar 20. pii: S1076-6332(20)30143-4. doi: 10.1016/j.acra.2020.03.002. [Epub ahead of print] and titled: Imaging Features of Coronavirus disease 2019 (COVID-19):…

Continue ReadingImaging Features of Coronavirus disease 2019 (COVID-19): Evaluation on Thin-Section CT.

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.

A new interesting article has been published in J Microbiol Immunol Infect. 2020 Mar 11. pii: S1684-1182(20)30065-7. doi: 10.1016/j.jmii.2020.03.005. [Epub ahead of print] and titled: TH17 responses in cytokine storm…

Continue ReadingTH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.